-
From the Editor-in-Chief
COVID-19 and Cancer in 2022Is it the beginning of the end or the end of the beginning?
by William G. Nelson, MD, PhD
-
Access to Health Insurance Key to Disparities in Cancer OutcomesAs outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
by Jon Kelvey
-
Exploring Amino Acids’ Impact on Tumor GrowthResearchers are investigating how to match specific dietary changes with therapy to impede cancer progression.
by Thomas Celona
-
Understanding Stress and CancerA symposium at the AACR Annual Meeting explores how social factors contribute to elevated risk of cancer in some populations.
by Eric Fitzsimmons
-
The Impact of the RACE for Children ActLegislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but trials in people under 18 may take years to generate results.
by Marci A. Landsmann
-
Making Collaboration More Common for Rare CancersAn AACR Annual Meeting 2022 session highlights the impact of research advocacy partnerships for a variety of cancers.
by Marci A. Landsmann
-
Second DCIS Diagnoses May Not Be Related to Initial LesionDNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
by Eric Fitzsimmons
-
Forward Look
Adequate RepresentationMedical oncologist Lola Fashoyin-Aje describes the Food and Drug Administration’s efforts to make clinical trials more inclusive.
by Erin O'Donnell
-
Forward Look
Comparing Antibody-Drug Conjugates for Metastatic Breast CancerResults favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
by Kris Conner
-
Forward Look
Who Benefits From Immunotherapy?Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
by Delia O'Hara
Reports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
Designing Clinical Trials for the PatientChallenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
